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Editor: L. LeiboviciProphylaxis with ﬂuoroquinolones (FQ) during prolonged neu-
tropenia has been standard of care in many centres based on the
results of meta-analyses and a large prospective study performed in
Italy in patients with haematological malignancies. A meta-analysis
from 2005, which included studies published between 1973 and
2005, found signiﬁcantly lower rates of mortality, infections, and
fever episodes in patients receiving FQ prophylaxis [1]. The ran-
domized study by Bucaneve and colleagues reported signiﬁcantly
lower rates of fever episodes (65% vs. 85%) and bacteraemia (18% vs.
34%) in patients receiving prophylaxis with levoﬂoxacin, with no
signiﬁcant impact on mortality (3% vs. 5%) [2]. An updated meta-
analysis, which incorporated these data, conﬁrmed the beneﬁt of
FQ on fever, bacteraemia, and mortality, with a number-needed-to-
treat to prevent one death of 55 [3]. A meta-analysis limited only to
stem cell transplant patients, mainly autologous (ASCT), who were
not included in the Bucaneve trial, found lower rates of bacteraemia
and febrile episodes but no impact on mortality [4].
However, a decade later, considering the threat of increasing
antimicrobial resistance worldwide, the utility of FQ prophylaxis
has been questioned for two main reasons. First, doubts about its
efﬁcacy were prompted by high rates of resistance to FQ, reported
both in the community and in the hospital setting. Indeed,DOI of original article: https://doi.org/10.1016/j.cmi.2017.11.019.
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over 40% for E. coli in Slovakia, Bulgaria, Italy, and Cyprus, and over
60% for K. pneumonia in Romania, Slovakia, Poland, and Greece [5].
As patients with haematological malignancies usually undergo
repeated cycles of in-patient chemotherapy, they are likely to be
colonized by FQ-resistant pathogens. Second, the risk of inducing
or selecting multidrug-resistant (MDR) strains by prolonged and
repeated exposure to FQ has been reported. Indeed, the possibility
of FQ promoting infections caused by multidrug-resistant patho-
gens, such as those producing extended spectrum b-lactamase
(ESBL), has been observed [6], particularly in settings with a high
prevalence of resistant strains [7,8]. Indirect evidence concerning
this issue came from a large recent study which included 65 SCT
centres from 25 countries (Europe, Australia, Asia) reporting data
on 655 episodes of Gram-negative bacteraemia [9]. This obser-
vational trial reported that 45% of ASCT centres provided FQ
prophylaxis. The rates of resistance to b-lactams other than car-
bapenems andMDRwere signiﬁcantly higher in centres providing
versus those not providing ﬂuoroquinolone prophylaxis (respec-
tively, 36% vs. 13%, p 0.002 and MDR 35% vs. 8%, p <0.001) [9].
In this issue of Clinical Microbiology and Infection, Yeshurun et al.
[10] report ﬁndings of a single-centre retrospective study on the
effect of ciproﬂoxacin prophylaxis discontinuation on infectious
complications in patients with multiple myeloma and lymphoma
undergoing ASCT. The authors compared febrile episodes, infec-
tious complications (bacteraemia, pneumonia, and Clostridium
difﬁcile associated disease (CDAD)), and mortality in 177 patients
transplanted between March 2007 and October 2012 who received
prophylaxis with ciproﬂoxacin versus 179 patients transplanted
between October 2012 and July 2016 who did not receive any
antibiotic prophylaxis. During the second period, they observed
higher rates of febrile neutropenia (83.1% vs. 90.4%, p 0.002), bac-
teraemia (4.5% vs. 15%, p <0.0001), and pneumonia (6.2% vs. 12.3%,
p 0.04). The rate of CDAD did not change signiﬁcantly (2.8% vs. 6.7%,
p 0.08), and mortality was similar (2.3% vs. 1.1% p 0.4). The authors
concluded that patients with multiple myeloma and lymphoma
undergoing ASCT may beneﬁt from antibacterial prophylaxis with
ciproﬂoxacin.
Association between FQ prophylaxis and lower rate of bacter-
aemia in ASCT recipients, particularly with multiple myeloma, hasblished by Elsevier Ltd. All rights reserved.
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review on FQ prophylaxis in haematology patients with neu-
tropenia performed by the European Conference on Infections in
Leukemia (ECIL) group [8], found that FQ might still prevent in-
fectious episodes, particularly in settings of low prevalence of MDR
strains, such as in the Yeshurun et al. cohort, in which no patient
was colonized with any MDR strain [10]. Other recent studies with
similar retrospective comparisons with historical cohorts evaluated
the effect of discontinuing prophylaxis. While some, but not all,
reported higher rates of bacteraemia with no prophylaxis, none of
them, even one that included 1987 patients, found any difference in
mortality [8].
The crucial issue is the clinical beneﬁt of a reduction in fever
and/or bacteraemia episodes, usually caused by susceptible strains,
in times of the need of antibiotic stewardship due to a worldwide
increase in MDR strains. Yeshurun et al. assumed that as bacter-
aemia was associated with higher mortality (8.6% vs. 0.8% at
30 days) and ciproﬂoxacin prophylaxis was associated with a lower
rate of bacteraemia, the prophylaxis would result in lower mor-
tality. However, the mortality in neutropenic patients with bac-
teraemia is inﬂuenced mostly by the time between the onset of
infection and the administration of appropriate antibiotic therapy
[13]. Bacteraemia episodes that can be prevented by ciproﬂoxacin
are typically caused by susceptible bacteria, and as such, empirical
therapy would be effective against them and they should not result
in increased mortality. Bacteraemia-associated mortality is usually
caused by MDR pathogens, which are unlikely to be prevented by
FQ [12,14]. For example, in a recent multicentre study, 78% of
carbapenem-resistant Enterobacteriaceae were resistant to FQ [9].
This study also noted that the negative impact on survival was
mainly caused by infections caused by resistant Gram-negative
pathogens, which are unlikely to be prevented by FQ prophylaxis.
A recent observational study from Italy which included 1625 ASCT
recipients, reported that infections caused by resistant pathogens
were predominantly responsible for increased mortality [12]. The
probability of survival at 4 months from transplant in 1479 patients
who did not develop bacteraemia because of Gram-negative bac-
teria was 97.5%, compared with 98.4% in 63 patients with
cephalosporin-susceptible E. coli infection (p 0.66), 93.1% in 29
patients with cephalosporin-non-susceptible but carbapenem-
susceptible E. coli infection (p 0.13), but only 66.7% in six patients
with carbapenem-resistant K. pneumoniae infections (p <0.0001)
[12]. This might explain the lack of effect of FQ prophylaxis on
mortality despite the presence of a reduced rate of infection, re-
ported also in other recent studies [8].
Two recent guidelines invite the readers to interpret the data in
the light of the lack of signiﬁcant beneﬁt onmortality, and despite a
possible reduction in the rate of infection and fever episodes in
some settings, they do not recommend FQ prophylaxis [15,16]. This
cautious policy is in agreement with what we, on behalf of the ECIL
group, have recently published [8].
In conclusion, it is unlikely that FQ prophylaxis would reduce
mortality, because (1) infections by susceptible strains are easily
treatedwith standard empirical therapy, and (2) mortality is mainly
driven by infections caused by pathogens resistant to standard
therapy employed in febrile neutropenia and to FQs. In the era of
increasing antibiotic resistance, even in settings with low preva-
lence of MDR bacteria so far, routine use of FQ prophylaxis should
be reconsidered. Further research should focus on rapididentiﬁcation of infecting pathogens and their susceptibility proﬁle
to allow for early start of adequate treatment even in case of
resistant bacteria.
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